The study is a prospective double-blind randomised placebo-controlled repeated cross-over trial and will be carried out at 2 sites, Chris O’Brien Lifehouse cancer centre and Royal Prince Alfred Hospital. It will enrol 32 adult patients with locally advanced or metastatic cancer who experience moderate to severe pain associated with cancer diagnosis requiring ongoing opioid analgesia. The study objectives include the measurement of pain severity, pain impact, side effects and quality of life.
Catalist-listed iX Biopharma has announced that its novel Wafermine sublingual ketamine wafers will be used in a study to evaluate its use as a treatment for pain suffered by patients with advanced cancer.
The pilot study will be funded by Chris O’Brien Lifehouse, a comprehensive cancer hospital in Camperdown, Sydney.
